Controlled clinical trial comparing flurbiprofen and phenylbutazone in patients with rheumatoid arthritis

Summary

Preliminary results in 12 patients with rheumatoid arthritis are presented from an ongoing double-blind, between patient comparison of flurbiprofen and phenylbutazone. Patients received either 300 mg flurbiprofen daily or 400 mg phenylbutazone daily over a 2-week treatment period. Two patients treated with phenylbutazone developed a rash, and treatment was discontinued in 1 of them after Day 2.

Key Words::

• Flurbiprofen
• phenylbutazone
• anti-inflammatory agents
• arthritis
• rheumatoid